Flavia Merigo

Dr. Flavia Merigo

orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 November 2010 in Journal of Neuroinflammation
Verified
Journal Article
Open access
PDF file
RBRoberta Bovolenta
Roberta Bovolenta
SZSilvia Zucchini
Silvia Zucchini
BPBeatrice Paradiso
Beatrice Paradiso
DRDonata Rodi
Donata Rodi
FMFlavia Merigo
Flavia Merigo
MSMichele Simonato
Michele Simonato
Under certain experimental conditions, neurotrophic factors may reduce epileptogenesis. We have previously reported that local, intrahippocampal supplementation of fibroblast growth factor-2 (FGF-2) and brain-derived neurotrophic factor (BDNF) increases neurogenesis, reduces neuronal loss, and reduces the occurrence of spontaneous seizures in a model of damage-associated epilepsy. Here, we asked if these possibly anti-epileptogenic effects might involve anti-inflammatory mechanisms. Thus, we used a Herpes-based vector to supplement FGF-2 and BDNF in rat hippocampus after pilocarpine-induced status epilepticus that established an epileptogenic lesion. This model causes intense neuroinflammation, especially in the phase that precedes the occurrence of spontaneous seizures. The supplementation of FGF-2 and BDNF attenuated various parameters of inflammation, including astrocytosis, microcytosis and IL-1β expression. The effect appeared to be most prominent on IL-1β, whose expression was almost completely prevented. Further studies will be needed to elucidate the molecular mechanism(s) for these effects, and for that on IL-1β in particular. Nonetheless, the concept that neurotrophic factors affect neuroinflammation in vivo may be highly relevant for the understanding of the epileptogenic process.

14 September 2019 in Cells
Verified
Journal Article
Open access
PDF file
RBRoberta Bonafede
Roberta Bonafede
JBJessica Brandi
Jessica Brandi
MMarcello Manfredi
Marcello Manfredi
ISIlaria Scambi
Ilaria Scambi
LSLorenzo Schiaffino
Lorenzo Schiaffino
RMRaffaella Mariotti
Raffaella Mariotti
Stem cell therapy represents a promising approach in the treatment of several neurodegenerative disorders, including amyotrophic lateral sclerosis (ALS). The beneficial effect of stem cells is exerted by paracrine mediators, as exosomes, suggesting a possible potential use of these extracellular vesicles as non-cell based therapy. We demonstrated that exosomes isolated from adipose stem cells (ASC) display a neuroprotective role in an in vitro model of ALS. Moreover, the internalization of ASC-exosomes by the cells was shown and the molecules and the mechanisms by which exosomes could exert their beneficial effect were addressed. We performed for the first time a comprehensive proteomic analysis of exosomes derived from murine ASC. We identified a total of 189 proteins and the shotgun proteomics analysis revealed that the exosomal proteins are mainly involved in cell adhesion and negative regulation of the apoptotic process. We correlated the protein content to the anti-apoptotic effect of exosomes observing a downregulation of pro-apoptotic proteins Bax and cleaved caspase-3 and upregulation of anti-apoptotic protein Bcl-2 α, in an in vitro model of ALS after cell treatment with exosomes. Overall, this study shows the neuroprotective effect of ASC-exosomes after their internalization and their global protein profile, that could be useful to understand how exosomes act, demonstrating that they can be employed as therapy in neurodegenerative diseases.

17 May 2011 in Journal of Anatomy
Verified
Journal Article
Closed access
PDF file
FMFlavia Merigo
Flavia Merigo
DBDonatella Benati
Donatella Benati
MCMirko Cristofoletti
Mirko Cristofoletti
FOFrancesco Osculati
Francesco Osculati
ASAndrea Sbarbati
Andrea Sbarbati

21 February 2018 in World Journal of Gastroenterology
Verified
Journal Article
Open access
FMFlavia Merigo
Flavia Merigo
ABAlessandro Brandolese
Alessandro Brandolese
SFSonia Facchin
Sonia Facchin
SMSilvia Missaggia
Silvia Missaggia
PBPaolo Bernardi
Paolo Bernardi
GSGiacomo Carlo Sturniolo
Giacomo Carlo Sturniolo
Glucose transporter expression in the human colon

18 February 2020 in Antioxidants
Verified
Journal Article
Open access
PDF file
SASajeela Ahmed
Sajeela Ahmed
NANaseer Ahmed
Naseer Ahmed
ARAlessio Rungatscher
Alessio Rungatscher
DLDaniele Linardi
Daniele Linardi
BKBibi Kulsoom
Bibi Kulsoom
GFGiuseppe Faggian
Giuseppe Faggian
Consumption of flavonoid-rich nutraceuticals has been associated with a reduction in coronary events. The present study analyzed the effects of cocoa flavonols on myocardial injury following acute coronary ischemia-reperfusion (I/R). A commercially available cocoa extract was identified by chromatographic mass spectrometry. Nineteen different phenolic compounds were identified and 250 mg of flavan-3-ols (procyanidin) were isolated in 1 g of extract. Oral administration of cocoa extract in incremental doses from 5 mg/kg up to 25 mg/kg daily for 15 days in Sprague Dawley rats (n = 30) produced a corresponding increase of blood serum polyphenols and become constant after 15 mg/kg. Consequently, the selected dose (15 mg/kg) of cocoa extract was administered orally daily for 15 days in a treated group (n = 10) and an untreated group served as control (n = 10). Both groups underwent surgical occlusion of the left anterior descending coronary artery and reperfusion. Cocoa extract treatment significantly reversed membrane peroxidation, nitro-oxidative stress, and decreased inflammatory markers (IL-6 and NF-kB) caused by myocardial I/R injury and enhanced activation of both p-Akt and p-Erk1/2. Daily administration of cocoa extract in rats is protective against myocardial I/R injury and attenuate nitro-oxidative stress, inflammation, and mitigates myocardial apoptosis.

1 November 2007 in Neoplasia
Verified
Journal Article
Open access
MGMirco Galiè
Mirco Galiè
Paolo FabenePaolo Fabene
Paolo Fabene
CNCRISTINA NANNI
CRISTINA NANNI
Antonello SpinelliAntonello Spinelli
Antonello Spinelli
ENElena Nicolato
Elena Nicolato
ASAndrea Sbarbati
Andrea Sbarbati
Glucose transport and consumption are increased in tumors, and this is considered a diagnostic index of malignancy. However, there is recent evidence that carcinoma-associated stromal cells are capable of aerobic metabolism with low glucose consumption, at least partly because of their efficient vascular supply. In the present study, using dynamic contrast-enhanced magnetic resonance imaging and [F-18]fluorodeoxyglucose (FDG) positron emission tomography (PET), we mapped in vivo the vascular supply and glucose metabolism in syngeneic experimental models of carcinoma and mesenchymal tumor. We found that in both tumor histotypes, regions with high vascular perfusion exhibited a significantly lower FDG uptake. This reciprocity was more conspicuous in carcinomas than in mesenchymal tumors, and regions with a high-vascular/low-FDG uptake pattern roughly overlapped with a stromal capsule and intratumoral large connectival septa. Accordingly, mesenchymal tumors exhibited a higher vascular perfusion and a lower FDG uptake than carcinomas. Thus, we provide in vivo evidence of vascular/metabolic reciprocity between epithelial and mesenchymal histotypes in tumors, suggesting a new intriguing aspect of epithelial-stromal interaction. Our results suggests that FDG-PET-based clinical analysis can underestimate the malignity or tumor extension of carcinomas exhibiting any trait of “mesenchymalization” such as desmoplasia or epithelial-mesenchymal transition.